Discovers and develops engineered monoclonal antibody therapeutics. Creates cytokine therapeutics for cancer and autoimmune diseases. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 14.4× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 42% of them.
Analysts' average target sits 41% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
The stock has been running stronger than the market lately.
Business Quality: Profit power and business quality trail similar companies in the sector.
Growth: Sales growth trails the sector average.
The stock trades 44% below its peak. The market has trimmed its expectations for the company.
The company sells $125.6M a year; the problem isn’t sales — it’s costs running above that number.
There is $547.7M in the vault; even if every debt were paid off, $360.0M would remain.
A loss of $91.9M against $125.6M in annual sales.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 25/100.
The growth engine is running at low revs right now. Report-card grade: 40/100.
On our five-subject report card, XNCR sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: XNCR’s sales are going backwards, and it closed last year at a loss. The road back runs through both.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (42/100) says the stock isn’t cheap.